The short version: Sermorelin is a synthetic 29-amino-acid fragment of growth hormone-releasing hormone (GHRH) that was once FDA-approved for diagnostic use in pediatric growth hormone deficiency, but the branded product was discontinued in 2008 and no current FDA-approved sermorelin product exists. The research peptide sold online is a laboratory reference chemical, not a medication. Before ordering, verify the supplier’s lot-specific certificate of analysis, confirm the testing laboratory is independent, and check that the listing maintains a strict research-use-only boundary. Stack Research publishes lot-specific documentation for its Sermorelin research peptide, which is the baseline standard any researcher should expect.
Search for “buy sermorelin” and you will find a market with price points that range from around $40 for a 5 mg vial on some research sites to over $200 for higher-concentration configurations. The spread is not explained by the cost of the raw material alone. It is explained by differences in sourcing, testing, documentation, and the degree to which each seller is willing to be transparent about what is actually in the vial.
This guide is written for laboratory researchers who need to evaluate a sermorelin supplier before placing an order. It covers what the published literature says about the compound, how the FDA’s regulatory posture toward sermorelin has changed over time, how to read a certificate of analysis without getting misled, and the specific questions that separate a transparent supplier from one that is hoping you will not ask.
What sermorelin is, and what the research shows
Sermorelin is a synthetic peptide composed of the first 29 amino acids of human growth hormone-releasing hormone (GHRH). The sequence is also referred to as GHRH(1-29) or GRF(1-29). It is the shortest synthetic peptide that retains the full biological activity of GHRH. NCATS Inxight Drugs describes sermorelin as a 29-amino-acid analog of human GHRH that binds to the GHRH receptor on the anterior pituitary and mimics native GRF in its ability to stimulate growth hormone secretion.
The mechanism is well characterized. Sermorelin activates the cAMP signaling pathway by binding to the pituitary GHRH receptor, stimulating the release of growth hormone in a physiological pulsatile pattern while maintaining negative feedback regulation. This distinguishes it from direct growth hormone injections, which can produce unnaturally high hormone levels. The pulsatile release pattern is considered closer to the body’s natural hormone rhythms, though the clinical significance of this difference is debated.
A review published in the journal Growth Hormone and IGF Research examined the diagnostic and therapeutic applications of GHRH and its analogs. The authors note that sermorelin was developed as a diagnostic agent for assessing pituitary somatotroph function and was subsequently investigated for therapeutic use in children with growth hormone deficiency. The review describes the compound’s pharmacokinetics and its ability to stimulate endogenous GH release without the supraphysiological peaks associated with exogenous GH administration.
A separate study published in the Journal of Clinical Endocrinology and Metabolism examined the effects of sermorelin on GH secretion in healthy older adults. The researchers found that sermorelin administration stimulated GH release in a dose-dependent manner, with the largest responses observed at higher doses. The study concluded that sermorelin retains its ability to stimulate GH secretion in older adults, though the magnitude of the response was lower than in younger subjects.
What the research does not establish is a safe and effective dose for any human use outside of a clinical trial setting. The clinical literature describes sermorelin in specific research contexts, with specific patient populations and monitoring protocols. Those conditions cannot be replicated by purchasing a research vial online and administering it without medical supervision.
The regulatory history of sermorelin in the United States
Sermorelin has a more complicated regulatory history than many research peptides. USADA’s guidance on sermorelin states that different formulations were approved by the FDA in 1990 and 1997 for the treatment of idiopathic growth hormone deficiency in children with growth failure, or for evaluating the ability of the pituitary to secrete growth hormone. Both formulations were discontinued in 2008.
The discontinuation was voluntary and was not for safety reasons. The manufacturer withdrew the branded product for commercial reasons, and no generic version entered the market. The practical result is that no FDA-approved sermorelin product currently exists in the United States. A DrugPatentWatch record for the original NDA notes that the product was not discontinued or withdrawn for safety or effectiveness reasons, but the commercial product is no longer marketed.
What emerged after the withdrawal was a market for compounded sermorelin. Licensed compounding pharmacies have prepared sermorelin under prescription for patients whose clinicians determine it is appropriate. The FDA has not placed sermorelin in Category 2 of bulk drug substances that may present significant safety risks, which means it remains eligible for compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. Peptide regulatory summaries describe sermorelin as retaining a clearer path to legitimate access through compounding than peptides such as BPC-157 that have been placed in Category 2.
The research peptide sold online occupies a different space entirely. It is labeled for laboratory research use only, not for diagnostic, therapeutic, or human use. The Stack Research Sermorelin product page states that the product is supplied only for lawful in-vitro laboratory or analytical research and that the page provides no dosing, administration, treatment, or diagnostic guidance. That boundary is the dividing line between a research supply business and a seller marketing an unapproved drug.
Why sermorelin is prohibited in sport
Sermorelin is prohibited at all times under the World Anti-Doping Agency’s Prohibited List. USADA explains that sermorelin is banned because of its ability to enhance muscle growth, endurance, and recovery by boosting endogenous growth hormone production. The agency notes that sermorelin use can cause side effects including swelling and edema in the arms, legs, and face, joint and nerve pain, and that sermorelin-induced GH excess can contribute to insulin resistance, increasing the risk of developing diabetes. Chronic GH excess is associated with hypertension, cardiac hypertrophy, and potentially cardiomyopathy.
USADA also warns that black market or unregulated sources of sermorelin may provide contaminated or mislabeled products, posing additional health risks. That warning is relevant to the research peptide market because it underscores the importance of analytical documentation. A vial that does not contain what the label claims is not a research input; it is an unknown substance.
Video: How sermorelin stimulates natural growth hormone
This third-party video provides general context on sermorelin research. It is not affiliated with Stack Research and is not a substitute for laboratory documentation or the published literature.
The researcher’s sourcing checklist for sermorelin
The difference between a defensible purchase and a gamble comes down to documentation. Here is what to check, in order.
1. Lot-specific certificate of analysis, not a generic sample
A certificate of analysis (COA) is only meaningful if it corresponds to the exact lot you are buying. A supplier that shows a single COA for “sermorelin” without tying it to a lot number is showing you marketing material, not a laboratory report. The COA should list the lot number, the testing laboratory, the report ID, the date the sample was received, and the date the results were published. If any of those fields are missing, the document cannot be used to verify the vial in your hand.
Stack Research publishes a lot-specific report for its Sermorelin 10 mg research peptide. The current lot documentation shows HPLC purity of 99.2 percent, measured content of 10.4 mg, and passing results for identity, bacterial endotoxin, and sterility. The report identifies the testing laboratory as Accumark Labs and includes a report ID that can be cross-referenced. The product page shows the exact SKU, lot number, laboratory, report ID, and sample dates alongside the price.
2. What the COA actually tests
A certificate that lists only “purity: 99%” is incomplete. The useful fields are identity, purity by HPLC, measured content, endotoxin, and sterility. Identity confirms the peptide sequence matches the reference standard. Purity by HPLC shows the percentage of the sample that is the target compound. Measured content tells you how much peptide is actually in the vial, which can differ from the label. Endotoxin and sterility results speak to the handling conditions.
If a supplier’s COA omits measured content or endotoxin, that is a gap. It may not be a dealbreaker for every research context, but it is a data point about how thoroughly the supplier tests its material. A representative certificate of analysis for sermorelin acetate from a chemical supplier shows the structure a complete report should follow: product name, CAS number, lot number, molecular formula, molecular weight, purity result, method, and identity result.
3. The research-use-only boundary
Every legitimate research peptide supplier uses the research-use-only (RUO) designation. The RUO label means the product is not intended for diagnostic, therapeutic, or human use. It is a legal boundary, not a suggestion.
What to watch for is a supplier that uses the RUO label while simultaneously publishing dosing information, before-and-after photos, or customer testimonials about human use. The FDA’s warning letter to Xcel Research LLC cited sermorelin product descriptions including “enhanced muscle growth and repair” and “improved metabolism and fat loss” as evidence that the products were intended as drugs for human use. A supplier that maintains the boundary consistently is easier to trust because it is not trying to have it both ways.
4. Pricing and configuration transparency
Sermorelin vials are typically sold in 5 mg, 10 mg, and 20 mg configurations. The price per milligram should be calculable from the listing. If the listing obscures the vial size, bundles it with accessories, or requires a minimum order to see pricing, that is friction that makes comparison harder. Stack Research lists its 10 mg Sermorelin vial at $94.90 with volume pricing available to verified research accounts. The product page shows the exact SKU and lot information alongside the price, which makes the listing auditable.
5. The regulatory context around the compound
Researchers studying sermorelin should be aware that the compound’s regulatory status is more nuanced than many listings acknowledge. Sermorelin was FDA-approved for diagnostic use and pediatric growth hormone deficiency, but the branded product was discontinued in 2008. It remains eligible for compounding under Section 503A, which means it occupies a different regulatory space than peptides that have been placed in Category 2. The FDA’s compounding safety page provides the current list and the reasoning behind each inclusion.
How Stack Research approaches sermorelin documentation
Stack Research is a research peptide supplier that publishes lot-specific documentation for each product configuration. The company’s testing page describes the analytical methods used and the laboratories that perform the work. For researchers who need to verify a supplier before ordering, the relevant questions are whether the documentation is specific to the lot, whether the testing laboratory is named, and whether the results can be independently reviewed.
The Sermorelin product page shows the current lot report directly on the page, with the purity, measured content, endotoxin, and sterility results visible without requiring a separate download. The COA library collects the reports for all products so that researchers can compare documentation across configurations. The company maintains a research-use-only boundary throughout its product descriptions and does not publish dosing or administration guidance.
That last point is worth emphasizing because it is the dividing line the FDA has drawn in its enforcement actions. A supplier can sell research peptides and publish analytical documentation without crossing into human-use marketing. When a supplier stays on the research side of that line, the documentation becomes the primary basis for evaluating the product. When a supplier crosses the line, the documentation is no longer the main thing being sold.
Comparing sermorelin documentation standards
The table below outlines the documentation elements that separate a transparent listing from an incomplete one. It is not a ranking of suppliers but a framework for evaluating any listing you encounter.
| Documentation element | What a complete listing shows | Red flag if missing |
|---|---|---|
| Lot-specific COA | Report tied to the exact lot number, with testing lab named | Generic COA or no lot number |
| Identity test | Confirms peptide sequence matches reference standard | Purity percentage only, no identity result |
| Measured content | Actual peptide mass in the vial, not just label claim | No fill or content verification |
| Endotoxin and sterility | Pass/fail results for both | Omitted entirely |
| Research-use-only boundary | No dosing, administration, or human-use content | Testimonials, before/after photos, influencer dosing content |
| Price transparency | Vial size, price, and SKU visible together | Price hidden behind account creation or minimum order |
| Independent laboratory | Third-party lab named, report ID verifiable | In-house testing only, no independent verification |
The table is not a guarantee. A supplier can produce all of these documents and still be selling a product that does not match the report, which is why independent testing services exist. But a supplier that cannot produce the documents at all is not worth the time it takes to evaluate further.
Common questions researchers ask before buying sermorelin
Is sermorelin legal to buy for research purposes?
Sermorelin is not currently FDA-approved as a commercial product, but it remains eligible for compounding under Section 503A. Research peptides labeled for laboratory use occupy a different regulatory space. Researchers should purchase only from suppliers that maintain the research-use boundary and provide analytical documentation.
What purity should a sermorelin COA show?
Purity by HPLC above 95 percent is the typical threshold for research-grade peptides. Many suppliers report 98 to 99 percent or higher. The purity figure is only meaningful alongside identity and content results. A vial can be 99 percent pure and still contain less peptide than the label claims if the fill is off.
How do I verify that a COA is real?
Check that the testing laboratory is named and that the report ID can be cross-referenced. Some laboratories publish verification portals where a report ID can be entered to confirm the document’s authenticity. If a supplier cannot tell you which laboratory performed the test, the COA cannot be independently verified.
What is the difference between sermorelin and GHRH(1-29)?
They are the same compound. Sermorelin is the synthetic 29-amino-acid fragment of human GHRH, also referred to as GHRH(1-29) or GRF(1-29). Researchers should confirm the identity of any product by its COA, not by the brand name or research designation on the vial.
What should I do if a supplier’s listing makes health claims?
Treat it as a disqualifying signal. Health claims on a research peptide listing are the exact pattern the FDA has cited in warning letters. A supplier that describes what the peptide “does” for the body is marketing an unapproved drug, regardless of the research-use label elsewhere on the page.
Can I compare sermorelin documentation across suppliers?
Yes, and you should. The relevant fields are comparable across suppliers: purity, identity, measured content, endotoxin, sterility, and lot traceability. The guide to reading a certificate of analysis walks through each field and explains what a complete report should contain.
Important notice: This article is provided for educational and informational purposes only. It does not constitute medical, legal, or regulatory advice. Research peptides discussed here are sold exclusively for laboratory research use and are not approved by the FDA or any other regulatory agency for human or veterinary use. Nothing in this article should be construed as guidance for human consumption, dosing, or administration. Statements regarding dietary supplements and research compounds have not been evaluated by the FDA. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction. Always consult the product label, the certificate of analysis, and a qualified professional before making decisions about any substance.